Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect.

BACKGROUND Apomorphine infusion therapy remains under-used and there are no comparative studies of motor and non-motor effects of apomorphine infusion. METHODS In this paper we report preliminary results from an ongoing clinical observational "real life" surveillance-based study focused on effects of this therapy on non-motor symptoms and health-related quality of life in a group of patients on apomorphine. RESULTS Apomorphine infusion led to highly significant improvements in UPDRS 3 (p = 0.0003), UPDRS 4 (p = 0.0003), PDQ-8 (Parkinson's disease questionnaire, p = 0.001) and NMSS total (non motor symptoms scale, p = 0.0003). Furthermore, apomorphine was tolerated in patients with visual hallucinations, illusions and paranoid ideations while significant improvement in specific non-motor symptoms such as hyperhidrosis, nocturia, urgency of micturition, and fatigue was recorded. Levodopa equivalent dose decreased significantly (1077.81 ± 446.26 to 458.75 ± 282.29, p < 0.0001) and a large effect size of intervention was noted. In an untreated group no such improvement was noted. The number needed to treat (NNT) for improvement >1 SEM in the Apo group was calculated and was lower than 2 for >1 SEM improvement of UPDRS 3, NMSS, and PDQ-8 total scores. CONCLUSIONS This pilot observational study suggests that non-motor effects are evident with apomorphine therapy and patients suitable for apomorphine deteriorate in the absence of therapy.

[1]  M. Yahr,et al.  Parkinsonism: Onset, progression, and mortality , 2011, Neurology.

[2]  D. Torgerson,et al.  Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design , 2010, BMJ : British Medical Journal.

[3]  D. Grosset,et al.  Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines , 2010, BMJ : British Medical Journal.

[4]  K. Chaudhuri,et al.  P2.149 Efflcacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease , 2009 .

[5]  M Zappia,et al.  International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease , 2009, Neurology.

[6]  I. Forgacs,et al.  Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[8]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. Rejas,et al.  Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. , 2008, Journal of clinical epidemiology.

[10]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[11]  G. Guyatt,et al.  Interpreting the results of patient reported outcome measures in clinical trials: The clinician's perspective , 2006, Health and quality of life outcomes.

[12]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  Andrew Evans,et al.  Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.

[14]  Ross D Crosby,et al.  Defining clinically meaningful change in health-related quality of life. , 2003, Journal of clinical epidemiology.

[15]  Andrew J Lees,et al.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.

[16]  Andrew Lees,et al.  Apomorphine for Parkinson’s Disease , 2002, Practical Neurology.

[17]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[18]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[19]  L. Vacca,et al.  Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results , 2001, Neurological Sciences.

[20]  G K Wenning,et al.  Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[21]  D. Gladman,et al.  Methods for assessing responsiveness: a critical review and recommendations. , 2000, Journal of clinical epidemiology.

[22]  K. Chaudhuri,et al.  Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome , 1999, Acta neurologica Scandinavica.

[23]  P. Leigh,et al.  Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. , 1997, Parkinsonism & related disorders.

[24]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[25]  Lewis E. Kazis,et al.  Effect Sizes for Interpreting Changes in Health Status , 1989, Medical care.

[26]  C. Tamminga,et al.  Schizophrenic symptoms improve with apomorphine. , 1978, Science.

[27]  T. van Laar,et al.  Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. , 2010, Parkinsonism & related disorders.

[28]  R. Hays,et al.  Estimating clinically significant differences in quality of life outcomes , 2004, Quality of Life Research.

[29]  R. Fitzpatrick,et al.  The PDQ-8: Development and validation of a short-form parkinson's disease questionnaire , 1997 .

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[31]  W. Poewe,et al.  Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. , 1993, Advances in neurology.

[32]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[33]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .